6 Results for "

CycK

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "CycK" in MCE Product Catalog:

Cat. No.: HY-E70660
Target:  

CDK

Research Areas:  

Cancer

CDK13/CycK Recombinant Human Active Protein Kinase is a RNA polymerase II C-terminal domain kinases. CDK13 interacts with the splicing factor SRSF1 and to regulate alternative splicing of HIV .
loading...
    loading...
Cat. No.: HY-E70659
Target:  

CDK

Research Areas:  

Cancer

CDK12/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II), thereby regulating different phases of the transcription cycle from transcription initiation to elongation and termination .
loading...
    loading...
Cat. No.: HY-E70658
Target:  

CDK

Research Areas:  

Cancer

CDK12 R722C/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase and regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability .
loading...
    loading...
Cat. No.: HY-RS18467
Research Areas:  

Others

Ccnk Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccnk gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-181405
CAS No.: 2387704-74-5
Target:  

Molecular Glues CDK

Research Areas:  

Cancer

SR-5037 is an orally active CDK12 (IC50 = 31 nM)/CDK13 inhibitor and CycK (DC50 = 30 nM; Dmax > 98%) molecular glue degrader. SR-5037 inhibits the enzymatic activity of CDK12/CycK and CDK13/CycK complexes. SR-5037 promotes the recruitment of DDB1 to the CDK12/CycK complex, thereby triggering proteasome-mediated CycK degradation. SR-5037 degrades active CycK in mouse models of triple-negative breast cancer. SR-5037 can be used in the research of cancers such as triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-180355
CAS No.: 2365230-48-2
Target:  

CDK Ser/Thr Kinase c-Myc

Research Areas:  

Cancer

SY-5102 is a potent, selective, and orally active cyclin-dependent kinase (CDK7) inhibitor with a Kd value of 0.03 nM. SY-5102 occupies the ATP-binding pocket of CDK7 via non-covalent binding to inhibit CDK7 activity, and downregulates its phosphorylation of cyclin CDK and RNA polymerase II. SY-5102 inhibits cancer cell proliferation, and induces tumor growth inhibition and regression. SY-5102 can be used in research related to triple-negative breast cancer .
loading...
    loading...